CClinicalTrials.gg
CompletedNCT04001530Updated Jul 6, 2021

Half-normal Saline in Atrial Flutter Ablation

An interventional study of Half Normal Saline 0.45% Infusion Solution Bag and Normal Saline 0.9% Infusion Solution Bag in Atrial Flutter, sponsored by Sunnybrook Health Sciences Centre. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-06.

Sponsored by Sunnybrook Health Sciences Centre · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Jan 2018, registered Jun 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To assess the acute and long-term efficacy of half-normal saline compared to normal saline for irrigation of open-irrigated catheters during catheter ablation for the treatment of cavotricuspid isthmus dependent atrial flutter.

Read the detailed description

It is unclear whether ionic strength affects energy delivery and ablation lesion size during radiofrequency ablation for atrial flutter. Given that saline contains ionic sodium and chloride in the solution, it has conductive properties that may disperse radiofrequency energy away from the tip-tissue interface, thereby reducing current density and lesion size compared to ablation with nonionic solutions. The efficacy of half-normal saline will be measured by the time taken to create bidirectional block across the cavotricuspid isthmus as well as the acute recurrence rate within 30 minutes of the initial occurrence of bidirectional block and the 1 year freedom from flutter recurrence.

02

Conditions studied

  • Atrial Flutter

Browse trials for

03

In context

Atrial Flutter

213 studies on the registry are indexed under Atrial Flutter; 50 are open to participants now.

This study's enrollment of 4 is below the median of 134 across 145 interventional studies indexed under Atrial Flutter.

Browse Atrial Flutter studies →

Lead sponsor

Sunnybrook Health Sciences Centre is the lead sponsor of 566 studies on the registry; 134 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients > 18 years of age at the time of enrollment
  • Patients presenting for right sided typical atrial flutter ablation who have a clinical indication to undergo catheter ablation
  • Fully informed written informed consent by either the subject or subject's legal representative and ability for subject to comply with study responsibilities

Exclusion criteria

Exclusion Criteria:

  • The presence of thrombus within the left atrial appendage
  • Prior catheter ablation of the cavotricuspid isthmus for right sided atrial flutter
  • The inability to provide consent or comply with study requirements
  • A predicted life expectancy of \< 12 months
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Half-normal saline

    Use of half-normal saline (0.45% NaCl) as an irrigant for open-irrigated ablation catheters

    Drug: Half Normal Saline 0.45% Infusion Solution Bag

  • Active comparator
    Normal saline

    Use of normal saline (0.9% NaCl) as an irrigant for open-irrigated ablation catheters

    Drug: Normal Saline 0.9% Infusion Solution Bag

Interventions

  • DrugHalf Normal Saline 0.45% Infusion Solution Bag

    Randomization to half normal saline

  • DrugNormal Saline 0.9% Infusion Solution Bag

    Randomization to normal saline

06

What researchers measure

Primary outcomes

  1. Time taken to produce bidirectional block

    Time frame: intraprocedural

  2. Acute recurrence rate < 30 minutes of initial occurrence of bidirectional block

    Time frame: intraprocedural

  3. Freedom from atrial flutter recurrence

    Time frame: 1 year

Secondary outcomes

  1. Time taken for termination of atrial flutter

    Time frame: intraprocedural

  2. Total radiofrequency ablation time and procedural time

    Time frame: intraprocedural

Other outcomes

  1. Incidence of procedure-related complications

    pericardial effusion due to cardiac perforation or pericarditis, transient ischemic attack/stroke, systemic embolism, phrenic nerve injury, pulmonary vein stenosis, atrio-esophageal fistula, death

    Time frame: at the time of the procedure and up to 1 month

  2. Incidence of steam pops

    marker of excessive heating of the tissue

    Time frame: periprocedural

07

Study locations

1 site
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
08

References and documents

Individual participant data

Plan to share: Undecided — Multicentre study, patient data deidentified for post-enrolment analysis

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04001530
Lead sponsor
Sunnybrook Health Sciences Centre
Responsible party
Dr. Benedict Glover (Staff electrophysiologist Schulich Heart Program, Associate Professor University of Toronto, Sunnybrook Health Sciences Centre) — Principal investigator
First posted
Jun 28, 2019
Start date
Jan 1, 2018
Primary completion
Jan 31, 2021
Completion
Jan 31, 2021
Last update
Jul 6, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion